1. Home
  2. MRNA vs KVYO Comparison

MRNA vs KVYO Comparison

Compare MRNA & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRNA
  • KVYO
  • Stock Information
  • Founded
  • MRNA 2010
  • KVYO 2012
  • Country
  • MRNA United States
  • KVYO United States
  • Employees
  • MRNA 5800
  • KVYO N/A
  • Industry
  • MRNA Biotechnology: Biological Products (No Diagnostic Substances)
  • KVYO
  • Sector
  • MRNA Health Care
  • KVYO
  • Exchange
  • MRNA Nasdaq
  • KVYO Nasdaq
  • Market Cap
  • MRNA 10.3B
  • KVYO 10.1B
  • IPO Year
  • MRNA 2018
  • KVYO 2023
  • Fundamental
  • Price
  • MRNA $25.90
  • KVYO $32.02
  • Analyst Decision
  • MRNA Hold
  • KVYO Buy
  • Analyst Count
  • MRNA 19
  • KVYO 21
  • Target Price
  • MRNA $48.13
  • KVYO $43.05
  • AVG Volume (30 Days)
  • MRNA 10.5M
  • KVYO 1.9M
  • Earning Date
  • MRNA 07-31-2025
  • KVYO 08-06-2025
  • Dividend Yield
  • MRNA N/A
  • KVYO N/A
  • EPS Growth
  • MRNA N/A
  • KVYO N/A
  • EPS
  • MRNA N/A
  • KVYO N/A
  • Revenue
  • MRNA $3,177,000,000.00
  • KVYO $1,007,298,000.00
  • Revenue This Year
  • MRNA N/A
  • KVYO $27.79
  • Revenue Next Year
  • MRNA $9.87
  • KVYO $20.95
  • P/E Ratio
  • MRNA N/A
  • KVYO N/A
  • Revenue Growth
  • MRNA N/A
  • KVYO 33.95
  • 52 Week Low
  • MRNA $23.15
  • KVYO $21.26
  • 52 Week High
  • MRNA $138.07
  • KVYO $49.55
  • Technical
  • Relative Strength Index (RSI)
  • MRNA 46.10
  • KVYO 41.45
  • Support Level
  • MRNA $25.06
  • KVYO $33.11
  • Resistance Level
  • MRNA $28.72
  • KVYO $34.93
  • Average True Range (ATR)
  • MRNA 1.18
  • KVYO 1.25
  • MACD
  • MRNA -0.18
  • KVYO -0.25
  • Stochastic Oscillator
  • MRNA 20.34
  • KVYO 3.45

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: